Skip to main content
. 2020 Sep 24;197(6):474–486. doi: 10.1007/s00066-020-01685-x

Table 5.

Toxicities by CTCAE v4.05

Toxicity Early (beginning of treatment up to 3 months after completion) (%) Late (3 months and later) (%)
GI
None N = 5 (16) N = 20 (64)
Mild (Grade I–II) N = 21 (68) N = 2 (7)
Severe (Grade III–IV) N = 1 (3) N = 1 (3)
Not reported N = 4 (13) N = 8 (26)
GU
None N = 11 (35) N = 21 (68)
Mild (Grade I–II) N = 16 (52) N = 5 (16)
Severe (Grade ≥III) N = 0 (0) N = 0 (0)
Not reported N = 4 (13) N = 5 (16)
Vaginitis
None N = 9 (29) N = 20 (64)
Mild (Grade I–II) N = 20 (64) N = 2 (7)
Severe (Grade ≥III) N = 0 (0) N = 0 (0)
Not reported N = 2 (7) N = 9 (29)
Hematotoxicity
Leukopenia
None N = 0
Grade I–II N = 22 (71)
Grade III N = 8 (26)
Grade IV N = 1 (3)
Anemia
None N = 8 (26)
Grade I–II N = 20 (64)
Grade III N = 3 (10)
Thrombopenia
None N = 20 (64)
Grade I–II N = 8 (26)
Grade III N = 2 (7)
Grade IV N = 1 (3)

GI gastrointestinal toxicity, GU genitourinary toxicity, dysuria